Sabra Health Care upgraded to Outperform from Market Perform at JMP Securities

JMP Securities upgraded Sabra Health Care (SBRA) to Outperform from Market Perform with a $20 price target The firm expects “multiple tailwinds to result in outsized returns” for the stock. Sabra will have a “unique and value-creating year” in 2025 for multiple reasons, including its tenant operating troubles related to the pandemic being functionally over, the analyst tells investors in a research note. Further, JMP says the company’s skilled nursing rent coverage ratios should continue to expand given the reporting methodology and a strong Medicaid rate environment. Third, Sabra’s senior housing assets are poised for multi-year growth due to a significant shortfall of development, contends the firm.